Congcong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Congcong Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Fan Zhang
Beijing Anzhen Hospital, Key Laboratory of Remodeling-related Cardiovascular Diseases, Beijing Institute of Heart, Lung and Vascular Diseases, Capital Medical University, Ministry of Education, Beijing, China
3 shared publications- Haibo Zhang
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publications Kexin Yao
Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Vascular Diseases, Capital Medical University, Beijing, China
2 shared publicationsNaixuan Cheng
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publications- Chengxiong Gu
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication - Fan Zhang
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 817
Serum peptidomics profiling reveals fibrinogen alpha chain-derived peptides associated with clinical outcome in patients with heart failure
There is an urgent need for effective risk prediction tools to assess all-cause mortality in heart failure (HF) patients, and recent serum peptidomics advancements may help identify potential biomarkers associated with HF outcome. We aimed to provide insights into the multiple biological processes and assess the predictive values of serum peptidomics in HF. We performed a prospective, nested, case-control study of 108 patients with HF. The serum peptides were measured by mass spectrometry in 27 healthy controls (HC), 27 patients who experienced all-cause death (event group), and 27 patients matched for age and sex who survived (non-event group) during 1-year follow-up. Bioinformatics analysis was conducted to identify changes in signaling pathways during the development of HF and screen candidate circulating peptides. We identified 1343 and 215 differential expressed peptides in the comparison between HF and HCs group and between the event and non-event group, respectively. Biological pathway analysis showed that the differentially expressed peptides were both mainly enriched in the coagulation and complement and coagulation cascades pathway. In addition, we identified key peptides with potential predictive value for HF outcome, particularly the fibrinogen alpha chain (FIBA)-derived peptides. Our findings suggest that the complement and coagulation pathway was associated with HF outcome. A FIBA-derived serum peptides model can serve as an outcome classifier in patients with HF.
- 17 November 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 817
Open AccessSerum peptidomics profiling reveals fibrinogen alpha chain-derived peptides associated with clinical outcome in patients with heart failure
There is an urgent need for effective risk prediction tools to assess all-cause mortality in heart failure (HF) patients, and recent serum peptidomics advancements may help identify potential biomarkers associated with HF outcome. We aimed to provide insights into the multiple biological processes and assess the predictive values of serum peptidomics in HF. We performed a prospective, nested, case-control study of 108 patients with HF. The serum peptides were measured by mass spectrometry in 27 healthy controls (HC), 27 patients who experienced all-cause death (event group), and 27 patients matched for age and sex who survived (non-event group) during 1-year follow-up. Bioinformatics analysis was conducted to identify changes in signaling pathways during the development of HF and screen candidate circulating peptides. We identified 1343 and 215 differential expressed peptides in the comparison between HF and HCs group and between the event and non-event group, respectively. Biological pathway analysis showed that the differentially expressed peptides were both mainly enriched in the coagulation and complement and coagulation cascades pathway. In addition, we identified key peptides with potential predictive value for HF outcome, particularly the fibrinogen alpha chain (FIBA)-derived peptides. Our findings suggest that the complement and coagulation pathway was associated with HF outcome. A FIBA-derived serum peptides model can serve as an outcome classifier in patients with HF.
- Open Access
- 10 August 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-12
Complement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice
Mutations in fibrillin 1 (FBN1) is the main cause of Marfan syndrome (MFS) with thoracic aortic aneurysm (TAA) as the main complication. Activation of the complement system plays a key role in the formation of thoracic and abdominal aortic aneurysms. However, the role of the complement system in MFS-associated aortic aneurysms remains unclear. In this study, we observed increased levels of complement C3a and C5a in the plasma of MFS patients and mouse, and the increased deposition of the activated complement system product C3b/iC3b was also observed in the elastic fiber rupture zone of 3-month-old MFS mice. The expression of C3a receptor (C3aR) was increased in MFS aortas, and recombinant C3a promoted the expression of cytokines in macrophages. The administration of a C3aR antagonist (C3aRA) attenuated the development of thoracic aortic aneurysms in MFS mice. The increased inflammation response and matrix metalloproteinases activities were also attenuated by C3aRA treatment in MFS mice. Therefore, these findings indicate that the complement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice.
- 10 August 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-12
Open AccessComplement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice
Mutations in fibrillin 1 (FBN1) is the main cause of Marfan syndrome (MFS) with thoracic aortic aneurysm (TAA) as the main complication. Activation of the complement system plays a key role in the formation of thoracic and abdominal aortic aneurysms. However, the role of the complement system in MFS-associated aortic aneurysms remains unclear. In this study, we observed increased levels of complement C3a and C5a in the plasma of MFS patients and mouse, and the increased deposition of the activated complement system product C3b/iC3b was also observed in the elastic fiber rupture zone of 3-month-old MFS mice. The expression of C3a receptor (C3aR) was increased in MFS aortas, and recombinant C3a promoted the expression of cytokines in macrophages. The administration of a C3aR antagonist (C3aRA) attenuated the development of thoracic aortic aneurysms in MFS mice. The increased inflammation response and matrix metalloproteinases activities were also attenuated by C3aRA treatment in MFS mice. Therefore, these findings indicate that the complement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice.
- Open Access
- 19 April 2022
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-6
A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement
Objective: To explore the role of genetic testing of VKORC1 and CYP2C9 in determining the dosage of warfarin after aortic valve replacement. Methods: A total of 172 patients receiving warfarin after aortic valve replacement were divided into a control group (n = 86) and an experimental (n = 86) group based on acceptance of genetic testing. In the experimental group, three loci of VKORC1 and CYP2C9 were tested by polymerase chain reaction-restriction fragment length polymorphism technique, and the initial dose of warfarin was determined based on the genetic testing results and warfarin oral-dose table recommended by U.S. Food and Drug Administration (FDA). In the control group, warfarin (3 mg per night) was used as the initial dose. The international normalized ratio (INR) of each patient was continuously monitored after medication. The percentages of patients meeting the target INR in the two groups at specific time points and at 3-month follow-up after discharge from the hospital were monitored, and the incidence of various adverse events was compared between the groups. Results: Based on the results of genetic testing, 68 patients received 3–4 mg/d (79.1%), 10 patients received 0.5–2 mg/d (11.6%), and eight patients received 5–7 mg/d (9.3%) as the initial dosages of warfarin in the experimental group. The percentages of the patients meeting the target INR on the third and sixth day of postoperative medication were 45.3% and 73.3%, respectively, in the experimental group, and 29.8% and 58.3%, respectively, in the control group. The INR critical values during hospitalization occurred in 2.3% in the experimental group and in 7.1% in the control group, while the percentage of the patients meeting the target INR after 3 months was 86.1% in the experimental group and 83.1% in the control group. Conclusion: Genetic testing may guide the selection of the initial dose of warfarin after heart valve replacement to rapidly achieve a stable dose.
- 19 April 2022
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-6
Open AccessA clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement
Objective: To explore the role of genetic testing of VKORC1 and CYP2C9 in determining the dosage of warfarin after aortic valve replacement. Methods: A total of 172 patients receiving warfarin after aortic valve replacement were divided into a control group (n = 86) and an experimental (n = 86) group based on acceptance of genetic testing. In the experimental group, three loci of VKORC1 and CYP2C9 were tested by polymerase chain reaction-restriction fragment length polymorphism technique, and the initial dose of warfarin was determined based on the genetic testing results and warfarin oral-dose table recommended by U.S. Food and Drug Administration (FDA). In the control group, warfarin (3 mg per night) was used as the initial dose. The international normalized ratio (INR) of each patient was continuously monitored after medication. The percentages of patients meeting the target INR in the two groups at specific time points and at 3-month follow-up after discharge from the hospital were monitored, and the incidence of various adverse events was compared between the groups. Results: Based on the results of genetic testing, 68 patients received 3–4 mg/d (79.1%), 10 patients received 0.5–2 mg/d (11.6%), and eight patients received 5–7 mg/d (9.3%) as the initial dosages of warfarin in the experimental group. The percentages of the patients meeting the target INR on the third and sixth day of postoperative medication were 45.3% and 73.3%, respectively, in the experimental group, and 29.8% and 58.3%, respectively, in the control group. The INR critical values during hospitalization occurred in 2.3% in the experimental group and in 7.1% in the control group, while the percentage of the patients meeting the target INR after 3 months was 86.1% in the experimental group and 83.1% in the control group. Conclusion: Genetic testing may guide the selection of the initial dose of warfarin after heart valve replacement to rapidly achieve a stable dose.
- Open Access
- 22 October 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
miRNA Expression Profiling Uncovers a Role of miR-139-5p in Regulating the Calcification of Human Aortic Valve Interstitial Cells
Calcific aortic valve disease (CAVD) is the most common structural heart disease, and the morbidity is increased with elderly population. Several microRNAs (miRNAs) have been identified to play crucial roles in CAVD, and numerous miRNAs are still waiting to be explored. In this study, the miRNA expression signature in CAVD was analyzed unbiasedly by miRNA-sequencing, and we found that, compared with the normal control valves, 152 miRNAs were upregulated and 186 miRNAs were downregulated in calcified aortic valves. The functions of these differentially expressed miRNAs were associated with cell differentiation, apoptosis, adhesion and immune response processes. Among downregulated miRNAs, the expression level of miR-139-5p was negatively correlated with the osteogenic gene RUNX2, and miR-139-5p was also downregulated during the osteogenic differentiation of primary human aortic valve interstitial cells (VICs). Subsequent functional studies revealed that miR-139-5p overexpression inhibited the osteogenic differentiation of VICs by negatively modulating the expression of pro-osteogenic gene FZD4 and CTNNB1. In conclusion, these results suggest that miR-139-5p plays an important role in osteogenic differentiation of VICs via the Wnt/β-Catenin pathway, which may further provide a new therapeutic target for CAVD.
- 22 October 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
Open AccessmiRNA Expression Profiling Uncovers a Role of miR-139-5p in Regulating the Calcification of Human Aortic Valve Interstitial Cells
Calcific aortic valve disease (CAVD) is the most common structural heart disease, and the morbidity is increased with elderly population. Several microRNAs (miRNAs) have been identified to play crucial roles in CAVD, and numerous miRNAs are still waiting to be explored. In this study, the miRNA expression signature in CAVD was analyzed unbiasedly by miRNA-sequencing, and we found that, compared with the normal control valves, 152 miRNAs were upregulated and 186 miRNAs were downregulated in calcified aortic valves. The functions of these differentially expressed miRNAs were associated with cell differentiation, apoptosis, adhesion and immune response processes. Among downregulated miRNAs, the expression level of miR-139-5p was negatively correlated with the osteogenic gene RUNX2, and miR-139-5p was also downregulated during the osteogenic differentiation of primary human aortic valve interstitial cells (VICs). Subsequent functional studies revealed that miR-139-5p overexpression inhibited the osteogenic differentiation of VICs by negatively modulating the expression of pro-osteogenic gene FZD4 and CTNNB1. In conclusion, these results suggest that miR-139-5p plays an important role in osteogenic differentiation of VICs via the Wnt/β-Catenin pathway, which may further provide a new therapeutic target for CAVD.
- Open Access
- 12 April 2021
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 21 (1) , 1-12
MicroRNA-200b-3p promotes endothelial cell apoptosis by targeting HDAC4 in atherosclerosis
Background: Epicardial adipose tissue (EAT) shares the same microcirculation with coronary arteries through coronary arteries branches, and contributes to the development of atherosclerosis. MicroRNAs (miRNAs) are involved in the formation of atherosclerosis. However, the alteration of miRNA profile in EAT during atherosclerosis is still uncovered. Methods: The miRNA expression profiles of EAT from non-coronary atherosclerosis disease (CON, n = 3) and coronary atherosclerosis disease (CAD, n = 5) patients was performed to detect the differentially expressed miRNA. Then the expression levels of miRNA in other CON (n = 5) and CAD (n = 16) samples were confirmed by realtime-PCR. miR-200b-3p mimic was used to overexpress the miRNA in HUVECs. The apoptosis of HUVECs cells was induced by H2O2 and ox-LDL, and detected by Annexin V/PI Staining, Caspase 3/7 activity and the expression of BCL-2 and BAX. Results: 250 miRNAs were differentially expressed in EAT from CAD patients, which were associated with metabolism, extracellular matrix and inflammation process. Among the top 20 up-regulated miRNAs, the expression levels of miR-200 family members (hsa-miR-200b/c-3p, miR-141-3p and miR-429), which were rich in endothelial cells, were increased in EAT from CAD patients significantly. Upregulation of miR-200 family members was dependent on the oxidative stress. The overexpression of miR-200b-3p could promote endothelial cells apoptosis under oxidative stress by targeting HDAC4 inhibition. Conclusions: Our study suggests that EAT derived miR-200b-3p promoted oxidative stress induced endothelial cells damage by targeting HDAC4, which may provide a new and promising therapeutic target for AS.
- 12 April 2021
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 21 (1) , 1-12
Open AccessMicroRNA-200b-3p promotes endothelial cell apoptosis by targeting HDAC4 in atherosclerosis
Background: Epicardial adipose tissue (EAT) shares the same microcirculation with coronary arteries through coronary arteries branches, and contributes to the development of atherosclerosis. MicroRNAs (miRNAs) are involved in the formation of atherosclerosis. However, the alteration of miRNA profile in EAT during atherosclerosis is still uncovered. Methods: The miRNA expression profiles of EAT from non-coronary atherosclerosis disease (CON, n = 3) and coronary atherosclerosis disease (CAD, n = 5) patients was performed to detect the differentially expressed miRNA. Then the expression levels of miRNA in other CON (n = 5) and CAD (n = 16) samples were confirmed by realtime-PCR. miR-200b-3p mimic was used to overexpress the miRNA in HUVECs. The apoptosis of HUVECs cells was induced by H2O2 and ox-LDL, and detected by Annexin V/PI Staining, Caspase 3/7 activity and the expression of BCL-2 and BAX. Results: 250 miRNAs were differentially expressed in EAT from CAD patients, which were associated with metabolism, extracellular matrix and inflammation process. Among the top 20 up-regulated miRNAs, the expression levels of miR-200 family members (hsa-miR-200b/c-3p, miR-141-3p and miR-429), which were rich in endothelial cells, were increased in EAT from CAD patients significantly. Upregulation of miR-200 family members was dependent on the oxidative stress. The overexpression of miR-200b-3p could promote endothelial cells apoptosis under oxidative stress by targeting HDAC4 inhibition. Conclusions: Our study suggests that EAT derived miR-200b-3p promoted oxidative stress induced endothelial cells damage by targeting HDAC4, which may provide a new and promising therapeutic target for AS.